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BACKGROUND: The United States has a prison population of over 2 million people, of 
whom the American Diabetes Association, ADA estimates 4.8% (80,000+) have 
diabetes.1,2 Despite information available about the broad picture of prison care, there is 
a striking lack of literature on the state of diabetes care in prisons and the health of 
prisoners living with diabetes, despite the lifelong impacts that suboptimal care and self-
management during this period can have on the many incarcerated individuals who 
eventually re-enter civil society.3,4 Further, as illustrated by 12 prisoners with diabetes in 
Georgia having been recently reported to have died of acute diabetic ketoacidosis, 
improper care and self-management can be acutely fatal.5 The paucity of primary data 
inhibits efforts to improve the health of prisoners with diabetes, including advocacy 
efforts that could compel investment in a body of research that focuses on this 
population. 
 
OBJECTIVE: The overarching objective of this project was to quantify health disparities 
of prisoners with diabetes in North Carolina, which is a fundamental step in informing 
advocacy efforts and improvement in treatment for this group.  
 
METHODS: The mixed methods approach of this study included a qualitative survey of 
physicians within the UNC health system who have experience treating diabetes 
patients and b) a cross-sectional analysis comparing HbA1c, diabetic ketoacidosis, 
hypoglycemia between prisoners with diabetes, individuals who had been released from 
prison less than a year ago, and never incarcerated individuals using aggregated 
quantitative data on diabetes patients from April 4th, 2014-April 1st, 2020 from the North 
Carolina Translational and Clinical Sciences Institute (NC TraCs) Carolina Data 
Warehouse for Health (CDWH). 
 
RESULTS: Prisoners with type 1 diabetes (n=77) had a statistically significantly higher 
prevalence of ketoacidosis (p-value: 0.008) and hypoglycemia (p-value: <0.001), and 
higher average HbA1c (p-value: 0.000), than those who were not incarcerated 
(n=7748). Recently released prisoners with type 1 diabetes (n=16) also had a 
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statistically significantly higher prevalence for hypoglycemia (p-value: <0.001) and 
higher average HbA1c (p-value: 0.002) than non-prisoners with type 1 diabetes. 
Recently released prisoners (255) with type 2 diabetes had statistically significantly 
higher prevalence of ketoacidosis (p-value:<0.001) and hypoglycemia (p-value: 0.012) 
than those who were not incarcerated (n=197,357) while no statistically significant 
differences were found between active prisoners (1,250) and non-prisoners. Survey 
results and interviews identified a combination of factors that could be responsible for 
worse diabetes management seen amongst prisoners and recently released prisoners. 
These factors included the restrictive prison context that limits engagement in 
recommended diabetes self-management behaviors, lack of transitional diabetes care 
from prison to civil society, as well as uncertain and difficult social and economic 
circumstances among recently released prisoners that reduce adherence to self-
management. 
 
CONCLUSIONS: Prisoners with type 1 diabetes and recently released prisoners have 
worse glycemic management and greater prevalence of acute complications than 
individuals with diabetes who were never incarcerated. Results suggest that policy 
changes within prison and relating to the transition out of prison need to be made to 






Diabetes is a chronic condition that impacts the body’s ability to utilize the energy from 
food. When a person consumes carbohydrate, most of it is broken down into glucose 
which is then taken up by the bloodstream. In a person without diabetes, this rise in 
blood sugar levels causes the pancreas to release insulin which signals to the body’s 
cells to uptake the sugar from the blood. With diabetes this ability to take in sugar is 
compromised predominantly through two different ways with the reduced ability to 
produce insulin in type 1 diabetes and the cell’s resistance to insulin in type 2 diabetes.6 
HbA1c percentages are generally used as an imperfect method of assessing one’s 
management of their diabetes with a high HbA1c percentage indicating prolonged 
elevated sugar levels in the blood.7 Recently, mean HbA1c for those with type 1 
diabetes was found to be 8.4% while the American Diabetes Association recommends 
an A1c less than 7%.8,9   
 
Although the cause of Type 1 diabetes remains largely elusive, the condition develops 
when the body’s ability to produce insulin is almost entirely impaired due to auto-
immune destruction of the insulin producing islet cells of the pancreas.10 Without insulin 
to signal to cells to uptake glucose, the ability of the cells in the body to utilize glucose 
as energy is greatly reduced. Those with type 1 diabetes must administer exogenous 
insulin every day to survive, as well as maintain a cardioprotective lifestyle because of 
heightened risk of cardiovascular disease.  It is estimated that type 1 diabetes makes up 
5-10% of people who have diabetes and is typically diagnosed below 20 years of age, 
although the rate of diagnosis later in life is increasing over time.11  
 
Type 2 diabetes involves varying levels of impairment in the production, release, and 
uptake of insulin with triggering lifestyle factors being more understood as compared to 
type 1 diabetes. With type 2 diabetes the body’s cells develop a resistance to insulin 
from long term exposure to heightened circulating glucose levels that result from a 
confluence of diet, physical activity, genetic, and environmental factors. This in turn can 
cause the overstimulation of the pancreas islet cells to produce more insulin and lead to 
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islet cell death which then causes a shortage of insulin within the body as well.12 Type 2 
diabetes is most often diagnosed in older adults, but the rise in childhood obesity has 
increased prevalence of type 2 diabetes among the youth. Those with type 2 diabetes 
are encouraged to lose weight, eat healthy foods, and to increase activity levels.11 If a 
patient is unable to make the proper lifestyle changes or is not seeing the results 
needed then oral diabetes medications, such as Metformin and GLP-1 agonists and 
exogenous insulin injections, can be prescribed to also help maintain healthy glucose 
levels.13 
 
The CDC’s 2020 National Diabetes Statistics Report found that currently 34.2 
Americans have diabetes, and an additional 88 million Americans have prediabetes. 
The report also found that new cases were disproportionately higher in non-Hispanic 
blacks and people of Hispanic descent.14 This is especially relevant to this study since 




There are both chronic and acute complications associated with diabetes. Chronic 
complications include retinopathy, neuropathy, nephropathy, and increased risk of heart 
attacks. While chronic conditions are equally important, this project will focus on acute 
complications, specifically diabetic ketoacidosis and hypoglycemia. Ketoacidosis is the 
lowering of blood pH through the increased production of acidic ketones. When the 
body has an impaired ability to uptake glucose due to a lack of insulin or resistance to 
insulin, the body then increases the utilization of fat as a fuel source. Using fat as an 
energy source involves the creation of ketones as well.  
 
During normal body functions, a fraction of the acetyl-CoA from the oxidation of fatty 
acid are converted to ketone bodies, a fuel source for the brain, muscle, and heart. 
Under normal conditions, a balance of acetyl-CoA entering the TCA cycle or being used 
for ketone synthesis is reached which prevents the accumulation of ketones in the 
blood, but under conditions of low insulin these normal regulation pathways are altered 
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which ultimately leads to increased activities of ketone synthesis.16,17,18 These 
unbalanced levels of ketones lead to a lowering of the blood pH and eventually acidosis.  
 
Typical symptoms for diabetic ketoacidosis include excessive urination, thirst, 
confusion, nausea, and shortness of breath. Untreated ketoacidosis can lead to death, 
but fortunately death is very preventable if the signs of acidosis are recognized and 
acted on with a global mortality rate of 0.2-2%.19 Those with type 1 diabetes are more 
likely to experience acidosis than people with type 2 diabetes, but those with type 2 can 
still experience diabetic ketoacidosis as well.19 The prevalence of ketoacidosis among 
type 1 patients is not fully understood, but a meta-analysis found a prevalence range of 
0-128 per 1000 people with type 1 diabetes.20   
 
Hypoglycemia is a condition in which the body’s blood sugar levels are below the 
normal range, typically signified by a fasting blood sugar level below 70 mg/dL.21 Some 
symptoms of hypoglycemia include: fatigue, shakiness, sweating, and confusion and 
loss of consciousness in more severe cases. Under normal bodily functions, the body is 
able to maintain a successful normal range of fasting sugar levels through insulin and 
glucagon signaling, but hypoglycemia can occur through the overstimulation of insulin 
production or when stored glucose is not able to successfully be released.21 In the case 
of diabetes, hypoglycemia can occur if the patient takes too much insulin or other 
diabetes medication in an effort to lower their blood sugar levels which then 
unintentionally causes their sugar levels to decrease beyond the desired normal range. 
Treatment for hypoglycemia typically involves the consumption of a fast-acting 
carbohydrate or, in more serious cases, the use of a glucagon kit to quickly elevate 
blood sugar levels.21 Similar to acidosis, hypoglycemia is more common among those 
with type 1 diabetes than type 2 with 1.15 severe hypoglycemic events per person year 
for type 1 and 0.35 for type 2.22 
 
Health of Prisoners 
There is currently a striking lack of literature on the health of prisoners with diabetes, but 
current literature and ongoing events suggests that diabetes care and health outcomes 
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are not equitable between prisoners with diabetes and their non-incarcerated peers. In 
2019, the Atlantic Journal-Constitution released an investigative journalism piece 
detailing the deaths of 12 prisoners with diabetes in Georgia who died from improper 
access to treatment for their diabetes management.5 Many of these inmates died from 
ketoacidosis due to the prisons refusing to administer insulin in a timely manner. Insulin 
was rejected on the grounds of prior positive drugs tests, or the need for insulin was 
ignored based on the incorrect judgement that the prisoner’s acidosis symptoms were 
drug withdrawal symptoms.5 As of March 2021, there is an ongoing federal class-action 
lawsuit against CoreCivic, a corrections corporation, for the allegations of having denied 
basic care for the prisoners’ diabetes at their facility in Tennessee.23 Additionally, in Feb 
2021 the state of Arizona was fined by a US district judge for not improving the quality 
of inmate care.24 Arizona specifically failed to provide newly prescribed medications to 
inmates within two days and for not informing inmates of medical results within five days 
of having received the medical records. These current events regarding the United 
States prison system suggests that multiple facilities across the country are failing to 
provide appropriate health care to their inmates. 
 
An international 2011 study from The Lancet found that the prevalence of many 
infectious and chronic diseases, including diabetes, were higher amongst prison 
populations than the general population in America when adjusted for age.3 Other 
literature suggests that 13.9% of federal and 20.1% of state inmates never receive a 
medical examination after their initial booking.4  Additionally, 20.9% of federal inmates 
and 24.3% of state inmates report having stopped taking their regular medication since 
they had been incarcerated.4 These statistics suggest that prisoners experience worse 
health and engage in fewer health-promoting behaviors as compared to the non-
incarcerated population. 
 
Once released from prison, the short-term health outlook for newly released prisoners is 
poor.  A retrospective cohort study conducted in Washington State found that when 
adjusted for age, sex, and race, the risk of death for former inmates was 3.5 times that 
of their non-incarcerated state peers and within the first two weeks of their release this 
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risk rises to an even greater 12.7 times that of those who weren’t incarcerated.25 The 
results from this retrospective cohort study display that intervention that addresses 
health barriers faced by recently released inmates is necessary to reduce the risk of 
death and achieve health equity. 
 
Barriers to Care 
The aforementioned studies suggest that prisoners with diabetes do not receive 
sufficient quality of care and do not engage in health promoting behaviors within the 
prison system and are not equipped with the behaviors or resources to maintain health 
once released from prison. It is important to highlight potential barriers to equitable 
diabetes care and self-management to both understand why prisoners may have worse 
health outcomes and highlight potential targets of intervention. When considering the 
following barriers, it is also crucial to consider how each barrier affects a patient 
differently based on whether they have type 1 or type 2 diabetes since the clinical needs 
and self-management of each are different. For example, a person with type 2 diabetes 
might be more concerned with barriers to healthy lifestyle habits, such as regular 
exercise, that slow the progression of type 2 diabetes or medication barriers since type 
2 diabetes can be treated with a wider array of drugs that take different approaches to 
treat the condition, such as SGLT2, DP-4, or alpha glucosidase inhibitors, sulfonylureas, 
thiazolidinediones, GLP-1 agonists, or amylin analogs.26 In contrast, a person with type 
1 diabetes could be more concerned about barriers to the administration of their insulin, 
barriers to appropriately time their meals and snacks with their insulin injection, and 
barriers to frequently checking their blood sugar levels.26  
 
A barrier to equitable clinical care that is intrinsic to incarceration is the disruption in 
continuity of care that a person with diabetes experiences once incarcerated. Studies 
have shown that having primary care provider continuity of care is correlated with 
superior management of glucose levels for patients with type 2 diabetes.27 In addition to 
the disruption in care that occurs when a person is removed from their community and 
incarcerated, a person may potentially experience further disruptions in their care if they 
are transferred to another facility within the prison system. Another important barrier to 
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equitable clinical care experienced by incarcerated individuals is the inability to 
administer their own insulin. This barrier is also somewhat inherent to prison since it is 
not feasible to allow prisoners to have access to the needles required to administer 
insulin due to safety concerns. However, the added hurdle of requiring a third party to 
administer insulin on the behalf of the prisoner with diabetes also increases opportunity 
for problems to arise because insulin administered too soon or too late relative to time 
of eating. According to North Carolina Department of Public Safety Regional Medical 
Director, Dr. Neva Bartholomew, the logistical challenge of properly timing insulin doses 
with meal times has also been exacerbated by COVID-19 due to larger meal time 
windows in an effort to space out eating groups.28 The added step of requiring a 
provider to administer insulin could also deter or preclude prisoners from obtaining an 
injection of insulin outside of their usual meal times prior to consuming a sugary snack 
bought from the prison commissary. 
 
Lastly, a different barrier to equitable clinical care involves the limitation of available 
medications for prisoners with diabetes, particularly affecting those with type 2 diabetes. 
According to a 2017 PEW report, prescriptions to prisoners are restricted by established 
formularies which list a limited selection of medications for each health condition.29 
Approved drugs on formularies are decided not only by their efficacy for treating health 
conditions, but also by their convenience of administration, susceptibility to abuse, and 
potential safety hazards associated with the physical container or delivery device.29 For 
example, formularies would avoid approving a drug that is delivered in a glass vial due 
to safety concerns that broken glass could present. While the medications listed on 
formularies are all viable, there is no denying that physicians treating prisoners with 
diabetes also have fewer easily accessible options at their disposal to help treat and 
manage diabetes. Regional Medical Director Bartholomew’s experience also supported 
this conclusion by confirming that prisoner diabetes patients generally have access to 
established diabetes drugs, such as Metformin, but have a much harder time being 




Recently released prisoners have barriers to care that are similar to the barriers faced 
by active prisoners, while also facing challenges that are unique to the transition out of 
prison. Much like active prisoners, the transition from incarceration involves the 
disruption in care that they had been previously receiving while in prison. Unlike active 
prisoners, those recently released from incarceration do not have the same 
constitutional right to healthcare that active prisoners receive. Once out of prison, many 
prisoners face similar situations where they no longer have health insurance since they 
can frequently fall into a gap where they do not qualify for Medicaid, but also cannot 
afford market rate health insurance.30 The 2012 Supreme Court decision in the case 
National Federation of Independent Business v Sebelius ruled that the expansion of 
Medicaid was unconstitutional and effectively made the expansion of Medicaid optional 
to individual states.31 As a result, states had the choice to implement the proposed 
expansion which entailed Medicaid coverage to those with incomes that are effectively 
138% that of the federal poverty level, or they could refuse the expansion and deny 
coverage to anyone with incomes above 100% of the poverty level. This has led to a 
situation where there is a health insurance coverage gap in which an individual can 
make too much money to qualify for Medicaid, but too little to qualify for health 
insurance tax credits.32 As of 2021, North Carolina is one of 12 states who have yet to 
expand coverage that would grant an estimated 215,000-500,000 North Carolinians 
coverage.33  
 
Even the people with diabetes transitioning out of prison who do qualify for Medicaid 
may face coverage gaps due to timeliness of Medicaid approval if they did not enroll in 
Medicaid prior to their release. The federal performance standard for processing 
Medicaid applications is 45 days. From 2011-2015 North Carolina processed fewer 
applications in a timely manner year over year with only 61% of applications being 
processed within 45 days from 2014-2015.34 This delay in coverage is problematic for 
any chronic condition, but especially so for those with diabetes requiring medications. 
Recently released prisoners can take advantage of community health clinics during a 
lapse in coverage, but even these resources have barriers. According to Dr. Evan 
Ashkin, founder and director of the North Carolina Formerly Incarcerated Transition 
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(FIT) Program, it can be difficult for a patient to schedule a timely appointment with a 
clinic and the copayments of $20-25 for an office visit and additional payments of $4-10 
for medications can sometimes pose a significant financial barrier for a recently 
released prisoner who does not have steady income.35  
 
Many of the barriers identified are barriers to clinical care, but it is also crucial to 
emphasize that barriers to the self-management of diabetes are just as important, if not 
more, than clinical care barriers. Prisoners could potentially be receiving clinical care 
that is not significantly different from non-incarcerated patients with diabetes, but if they 
have subpar self-management then their health outcomes will reflect that. Psychological 
barriers to adhere to diabetes self-management recommendations present a possible 
explanation for worse clinical outcomes for prisoners with diabetes as compared to non-
incarcerated individuals with diabetes. A meta-analysis estimated that the prevalence of 
depression for prisoners was 36.9% as compared to a 14.6% lifetime prevalence of 
depression within the general population and 21-27% within the population of those with 
diabetes.36 It is reasonable to consider the possibility that a prison environment, which 
appears to foster depressive symptoms potentially explained by the restriction of 
freedom or pessimism for one’s future, could increase a diabetes patients’ apathy 
towards proper maintenance of their health. This apathy could manifest in behavior 
detrimental towards the management of diabetes such as exercising less, checking 
blood sugar levels less often, and being less health conscientious when purchasing 
food from the commissary. 
 
One must also consider the added responsibilities that a person transitioning out of 
prison might experience when re-entering society that potentially complicate the 
adequate self-management of their diabetes such as finding housing, a source of 
income, and adhering to probation requirements.35 This transitional period of 
reintegrating into society can be overwhelming and may cause recently released 
prisoners with diabetes to deprioritize seeking medical treatment in favor of focusing on 




Despite prior literature identifying barriers to care and clinical health outcome inequities 
that exist based on prisoner status, to our knowledge, no such study has examined how 
diabetes specific health outcomes vary based on prisoner status in North Carolina. 






Specific Aims and Hypotheses 
 
Aim 1: Determine the prevalence of serious acute diabetic ketoacidosis and 
hypoglycemia complications amongst prisoners with diabetes, recently released 
prisoners with diabetes, and non-prisoners with diabetes. Perform a cross-
sectional comparison of average glucose levels, measured by HbA1C, between 
the three prisoner status groups to ascertain approximate diabetes management. 
1: Prisoners with diabetes will have the highest average HbA1c and highest prevalence 
of diabetic ketoacidosis and hypoglycemia due to the restrictive nature of prison. 
Recently released prisoners will display the second worse overall health outcomes as 
they transition back to non-incarcerated life. 
 
Aim 2- Determine barriers to care that prisoners with diabetes experience that 
non- prisoners with diabetes do not. 
2. Prisoners will have additional barriers to medication accessibility, exercise 







There were two distinct data sources used for this study. The first was the aggregated 
prisoner and civilian diabetes health data through the North Carolina Translational and 
Clinical Sciences Institute’s Carolina Data Warehouse for Health. The Carolina Data 
Warehouse for Health is a database containing medical information from the UNC 
Health Care System. The Carolina Data Warehouse for Health maintains a ratio of 
approximately 8,000 active incarcerated patients for every million active UNCHCS 
patients.37 This data was chosen for two main reasons. The first was due to the quality 
and mass quantity of data available within the database and the second was because it 
made available aggregated prisoner health data that is traditionally difficult to obtain.37 
The Carolina Data Warehouse for Health was only able to supply counts that were 
greater than 10 to prevent the deduction of individual patients’ identities. 
 
The aggregated health data from the Carolina Data Warehouse for Health was 
composed of visits to UNC healthcare clinics ranging from April 4th, 2014 through April 
1st, 2020. The patients were identified by type 1 or type 2 diabetes using a simple 
algorithm that sorted the patients based on a simple majority of type 1 diabetes (250.xx 
ICD-9 and E10.xx ICD-10 codes) or type 2 diabetes (250.xx ICD-9 and E11.xx ICD-10 
codes) ICD codes within the patient’s insurance billing. Previous literature on diabetes 
survey methods had established that a simple majority, or a 0.5 ICD ratio, had strong 
predictive values for successfully identifying the correct type of diabetes for a patient.38  
 
The following health measures were gathered for each cross-sectional group: total 
number of patients, cases of diabetic ketoacidosis, cases of hypoglycemia, and mean 
hemoglobin A1c. The prevalence of diabetic ketoacidosis, hypoglycemia, and the mean 
hemoglobin A1c served to assess the overall quality of diabetes care and management 




Case counts of diabetic ketoacidosis and hypoglycemia were gathered by the 
recognition of associated ICD-9 and ICD-10 codes within the patient’s insurance billing 
at the time of their visit during the requested date range for the data (specific ICD codes 
used can be found in the online supplemental file). The hemoglobin A1c was found 
within the patient health notes with the most recent A1c value being used if a patient 
had multiple visits. 
 
The patients were split into three different cross-sectional groups: patients with diabetes 
who were seen as an active prisoner, patients with diabetes who had not been 
incarcerated within the past twelve months from their visit date to a UNC clinic, and 
patients with diabetes who had been incarcerated within the past twelve months from 
their visit date to a UNC clinic who were not also being seen as an active prisoner. The 
intention behind including the last group was to explore possible residual impacts of 
incarceration on the health outcomes of patients. Additionally, each cross-sectional 
grouping was further split into type 1 or type 2 diabetes subgroups. Prisoners were 
identified by their North Carolina Department of Public Safety Payor Insurance 
information. Recently released prisoners were identified by a prior North Carolina 
Department of Public Safety Payor Insurance claim which was then followed up by a 
different insurance claim within 12 months of the NCDPS claim which would signify that 
the patient was no longer incarcerated but had been within the last 12 months.  
 
The second data source used during this study was generated by a survey that aimed 
to assess the differences in care that prisoners with diabetes receive compared to their 
non-prisoner counterparts, as determined by UNC medical providers. The views of the 
UNC medical providers served as an imperfect, but still useful proxy for direct 
experiences of prisoner patients themselves due to the difficulty of involving prisoners 
within a research study since they are a vulnerable group as determined by the 
Institutional Review Board.39 The survey developed by the research team was 
composed of linear Likert scale questions asking the participant to rate the impact of 
various aspects of prison on diabetes patient health such as the diabetes knowledge of 
prison officials, quality of diet, timing of meals, and ability to self-administer insulin, 
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amongst other questions. The survey also included short free response questions about 
potential benefits of prison on diabetes patient care, potential policy changes that would 
most benefit prisoner patients the most, and problems facing incarcerated diabetes 
patients related to COVID-19 in given the study period overlapped with the COVID-19 
pandemic. These questions were determined by identifying potential aspects of 
incarceration that could potentially impede clinical care and the seven self-care 
behaviors critical for diabetes management as determined by the American Association 
of Diabetes Educators.40 
 
The survey was sent through electronic mail to UNC medical providers via judgemental 
sampling and completed between June 1st, 2020 and December 31st, 2020. The 
surveys were sent to UNC medical providers based on whether their clinic in which they 
practiced treated diabetes patients. Additionally, the North Carolina Translational and 
Clinical Sciences Institute’s Carolina Data Warehouse for Health was used to create a 
shortlist of UNC clinics that have treated incarcerated patients with diabetes to help 
target survey efforts. The inclusion criteria for participation were as follows: 1) The 
participant was a practicing medical provider, 2) The participant regularly treated 
patients with diabetes, 3) The participant had experience treating incarcerated diabetes 
patients. Participant eligibility based on the criteria was self-determined. The consent 
process was embedded within the survey, immediately terminating participation in the 
survey if the participant chose not to consent.  
 
Statistical Analyses  
The data received from the North Carolina Translational and Clinical Sciences Institute’s 
Carolina Data Warehouse for Health was analyzed with global chi squared tests and 
ANOVA, stratified by diabetes type, to assess differences in the distribution of cases of 
acute complications (ketoacidosis or hypoglycemia) or mean HbA1c across the three 
comparison groups (prisoner, recently released prisoners, and non-prisoners). If the null 
hypothesis was rejected at an alpha level of 0.05 then pairwise tests of proportions and 
t-tests (Tukey post hoc tests) were then conducted to determine which groups were 
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statistically significantly different from one another at an alpha level adjusted for multiple 
comparisons (0.05/3). 
 
The medical provider surveys were analyzed by ranking the obstacles to equitable 
health outcomes from highest mean impact to lowest as perceived by the physicians 
who completed the survey. Qualitative results involving suggested policy changes were 
compiled and grouped together based on the main objective of the suggested change, 
i.e., dietary suggestions were grouped as one policy and insulin related suggestions 
were grouped as another. 
 
The next chapter is the manuscript to be submitted for publication in the American 
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Objective: To compare the health outcomes of prisoners and recently released 
prisoners with diabetes to the non-incarcerated population with diabetes. 
Methods: This study was conducted in North Carolina and used mixed methods 
utilizing surveys (June 2020-December 2020, n=13) and EHR data (April 2014-April 
2020, n=206,703) to assess barriers to care and quantify differences in health 
outcomes. 
Results: Prisoners and recently released prisoners with type 1 diabetes had statistically 
significantly higher prevalence of ketoacidosis, hypoglycemia, and worse HbA1c, than 
those who were not incarcerated. Recently released prisoners with type 2 diabetes had 
statistically significantly higher prevalence of ketoacidosis and hypoglycemia than those 
who were not incarcerated while no differences were found between active prisoners 
and non-prisoners. Survey results identified diabetes management barriers which 
included factors stemming from the restrictive and disruptive nature of prison and 
insufficient support when transitioning out of prison. 
Conclusions: The results suggest that prisoners and recently released prisoners with 
diabetes experience worse diabetes clinical outcomes than non-prisoners. 
Policy implications: Results suggest that policy changes within prison and relating to 








The United States has a prison population of over 2 million people, of whom the 
American Diabetes Association, ADA estimates 4.8% (80,000+) have diabetes.1,2 
Despite information available about the broad picture of prison care, there is a striking 
lack of literature on the state of diabetes care in prisons and the health of prisoners 
living with diabetes, despite the lifelong impacts that suboptimal care and self-
management during this period can have on the many incarcerated individuals who 
eventually re-enter civil society.3,4  Further, as illustrated by 12 prisoners with diabetes 
in Georgia having been recently reported to have died of acute diabetic ketoacidosis, 
improper care and self-management can be acutely fatal.5 The paucity of primary data 
inhibits efforts to improve the health of prisoners with diabetes, including advocacy 





There were two distinct methods used for this study. The first was the aggregated 
prisoner and civilian diabetes health data through the North Carolina Translational and 
Clinical Sciences Institute’s Carolina Data Warehouse for Health. The Carolina Data 
Warehouse for Health is a database containing medical information from the UNC 
Health Care System. The Carolina Data Warehouse for Health maintains a ratio of 
approximately 8,000 active incarcerated patients for every million active UNCHCS 
patients.6 This data was chosen for two main reasons. The first was due to the quality 
and quantity of data available within the database and the second was because it made 
available aggregated prisoner health data that is traditionally difficult to obtain.7 The 
Carolina Data Warehouse for Health was able to supply only counts that were greater 




The aggregated health data from the Carolina Data Warehouse for Health was 
composed of visits to UNC healthcare clinics ranging from April 4th, 2014 through April 
1st, 2020. The patients were identified by type 1 or type 2 diabetes using a simple 
algorithm that sorted the patients based on a simple majority of type 1 diabetes (250.xx 
ICD-9 and E10.xx ICD-10 codes) or type 2 diabetes (250.xx ICD-9 and E11.xx ICD-10 
codes) ICD codes within the patient’s insurance billing. Previous literature on diabetes 
survey methods had established that a simple majority, or a 0.5 ICD ratio, had strong 
predictive values for successfully identifying the correct type of diabetes for a patient.8  
 
The following health measures were gathered for each cross-sectional group: total 
number of patients, cases of diabetic ketoacidosis, cases of hypoglycemia, and mean 
hemoglobin A1c. The prevalence of diabetic ketoacidosis, hypoglycemia, and the mean 
hemoglobin A1c served to assess the overall quality of diabetes care and management 
within each cross-sectional group.   
 
Case counts of diabetic ketoacidosis and hypoglycemia were gathered by the 
recognition of associated ICD-9 and ICD-10 codes within the patient’s insurance billing 
at the time of their visit during the requested date range for the data (specific ICD codes 
used can be found in the online supplemental file). The hemoglobin A1c was found 
within the patient health notes with the most recent A1c value being used if a patient 
had multiple visits. 
 
The patients were split into three different cross-sectional groups: patients with diabetes 
who were seen as an active prisoner, patients with diabetes who had not been 
incarcerated within the past twelve months from their visit date to a UNC clinic, and 
patients with diabetes who had been incarcerated within the past twelve months from 
their visit date to a UNC clinic who were not also being seen as an active prisoner. The 
intention behind including the last group was to explore possible residual impacts of 
incarceration on the health outcomes of patients. Additionally, each cross-sectional 
grouping was further split into type 1 or type 2 diabetes subgroups. Prisoners were 
identified by their North Carolina Department of Public Safety Payor Insurance 
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information. Recently released prisoners were identified by a prior North Carolina 
Department of Public Safety Payor Insurance claim which was then followed up by a 
different insurance claim within 12 months of the NCDPS claim which would signify that 
the patient was no longer incarcerated but had been within the last 12 months.  
 
The second data source used during this study was generated by a survey that aimed 
to assess the differences in care that prisoners with diabetes receive compared to their 
non-prisoner counterparts, as determined by UNC medical providers. The survey 
developed by the research team was composed of Likert scaled questions regarding the 
impact of various aspects of prison on diabetes patient health such as the diabetes 
knowledge of prison officials, quality of diet, timing of meals, and ability to self-
administer insulin, amongst other questions.  These questions were determined by 
identifying potential aspects of incarceration that could potentially impede clinical care 
and the seven self-care behaviors critical for diabetes management as determined by 
the American Association of Diabetes Educators.9 The survey also included short free 
response questions about potential benefits of prison on diabetes patient care, potential 
policy changes that would most benefit prisoner patients, and problems facing 
incarcerated diabetes patients as related to COVID.   
 
The survey was sent through electronic mail to UNC medical providers via judgemental 
sampling and completed between June 1st, 2020 and December 31st, 2020. The 
surveys were sent to UNC medical providers working in clinics that commonly treated 
patients with diabetes (e.g., family practice, internal medicine). Additionally, the North 
Carolina Translational and Clinical Sciences Institute’s Carolina Data Warehouse for 
Health was used to create a shortlist of UNC clinics that have treated incarcerated 
patients with diabetes to help target survey efforts. The inclusion criteria for participation 
were as follows: 1) The participant had to be a practicing medical provider, 2) The 
participant must regularly treat patients with diabetes, 3) The participant had to have 
experience treating incarcerated diabetes patients. Participant eligibility based on the 
criteria was self-determined. The consent process was embedded within the survey, 
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terminating participation in the survey immediately if the participant chose not to 
consent.  All procedures were approved by the UNC institutional review board. 
 
Statistical Analyses  
Global chi squared tests and ANOVA, stratified by diabetes type, were conducted to 
determine if there were any differences in the distribution of cases of acute 
complications (ketoacidosis or hypoglycemia) or mean HbA1c across the three 
comparison groups (prisoner, recently released prisoners, and non-prisoners). If the null 
hypothesis was rejected at an alpha level of 0.05 then pairwise tests of proportions and 
t-tests (Tukey post hoc tests) were then conducted to determine which groups were 
statistically significantly different from one another at an alpha level 0.0167 (0.05/3). 
Ketoacidosis data for recently released prisoners with type 1 diabetes was censored 
due to counts less than 10. Due to this limitation, we ran a sensitivity analysis for the 
type 1 diabetes ketoacidosis global chi squared tests using a conservative case count 
value of 1 and a liberal case count of 9 for recently released prisoners. 
 
Medical provider surveys were analyzed by ranking the obstacles to equitable health 
outcomes from highest mean impact to lowest as perceived by the physicians who 
completed the survey. Qualitative results involving suggested policy changes were 
compiled and grouped together based on the main objective of the suggested change, 
i.e., dietary suggestions were grouped as one policy and insulin related suggestions 




The global chi squared test found that there were statistically significant differences at 
an alpha of 0.05 between the prisoner status groups for both type 1 and type 2 diabetes 
regarding the prevalence of ketoacidosis (Type 1 diabetes conservative case count p-
value: 0.02, liberal case count p-value: <0.001, type 2 diabetes p-value: <0.001, Table 
1). Follow up pairwise tests of proportions (alpha 0.05/3) found that for those with type 1 
diabetes the prevalence of ketoacidosis differed significantly between the active 
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prisoner group and the non-incarcerated group who had either never been incarcerated 
or were at least a year removed from incarceration (p-value: 0.008, Table 2). Post-hoc 
tests comparing the difference for the prevalence of ketoacidosis among recently 
released prisoners to active prisoners and never prisoners could not be run due to 
censored data. 
 
No statistically significant difference in ketoacidosis prevalence for people with type 2 
diabetes was found between active prisoners and the non-incarcerated status groups 
(p-value: 0.97, Table 2), however, there was a significant difference found when 
comparing recently released prisoners to active prisoners (p-value: 0.001, Table 2) and 
recently released prisoners to non-prisoners (p-value: <0.001, Table 2).  
 
The global chi squared test also found that there were statistically significant differences 
between the prisoner status groups for both type 1 and type 2 diabetes regarding the 
prevalence of hypoglycemic events requiring medical treatment (Type 1 diabetes: p-
value:<0.001, Type 2 diabetes: p-value: 0.006, Table 1). Among those with type 1 
diabetes, the pairwise tests of proportions indicated that the non-incarcerated group 
differed significantly from both active prisoners (p-value:<0.001, Table 2) and recently 
released prisoners (p-value: <0.001, Table 2). No statistically significant difference was 
found between the active prisoner and recently released prisoner groups (p-value: 0.18, 
Table 2). 
 
Among those with type 2 diabetes, results of the pairwise proportion tests found that the 
recently released prisoner group differed statistically significantly from the non-
incarcerated group with regards to the prevalence of hypoglycemic events requiring 
medical attention (p-value: 0.01, Table 2). No statistically significant differences were 
found between the active prisoner group to the non-incarcerated group (p-value: 0.04, 
Table 2) and the recently released prisoner status groups (p-value: 0.20, Table 2). 
 
The one-way ANOVA test found that the prisoner status groups differed significantly for 
mean HbA1c among those with both type 1 and type 2 diabetes (Type 1 diabetes: p-
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value: <0001, Type 2 diabetes: p-value: 0.0132, Table 3). The post-hoc t-tests indicated 
a statistically significant difference was found within type 1 diabetes when the non-
incarcerated group was compared to both active prisoners (HbA1c difference:-1.37, p-
value: <0.001, Table 2) and recently released prisoners (HbA1c difference: -1.81, p-
value: 0.002, Table 2). Mean HbA1c was not statistically significantly different between 
active prisoners and recently released prisoners (HbA1c difference:-0.44, p-value: 0.73, 
Table 2). For type 2 diabetes, post-hoc t-tests revealed no significant differences at an 
alpha of 0.05/3 when comparing the mean HbA1c of active prisoners to recently 
released prisoners (HbA1c difference: -0.49, p-value: 0.24, Table 2) and never 
prisoners (HbA1c difference: 0.20, p-value: 0.25, Table 2) or when comparing recently 
released prisoners to never prisoners (HbA1c difference: 0.69, p-value: 0.03, Table 2) 
 
The study included 13 physicians who met the required participation criteria to complete 
the survey on perceived barriers to care within prison. The overall mean impact of 
prison on the health of their patients was perceived to be 77/100 (0=No Impact, 
100=Large Impact, Table 4) while the top three obstacles to equitable care were 
deemed to be the timing of meals and snacks, the lack of freedom to self-administer 
insulin, and the quality of care received within prison (Table 4).  
 
Physicians believed that the following policy changes would improve the health of 
prisoners with diabetes and recently released prisoners with diabetes: 
● Improved utilization of diabetes protocols and nurse coordinators 
● Changes in diet/expanding dietary options and timing 
● Improved transitional care plan when exiting prison 
● Improving the array of medications available for people with type 2 diabetes 
● Improved access to endocrinologists and nutritionists through telemedicine 
● Greater freedom/ability to administer insulin 
 
Physicians perceived prison as having some benefits to patient health by providing 
regular access to care and medication that the prisoners might otherwise not receive 






The goal of this study was to help fill in the gaps of knowledge in literature as it pertains 
to diabetes specific health outcomes of prisoners and recently released prisoners with it 
currently being unclear if, and to what degree, the management of diabetes within 
prisons differs to the non-incarcerated population. Better understanding of this gap 
could help direct prison policy changes and future study efforts. 
    
Our main findings were that when compared to those who were not incarcerated, 
prisoners and recently released prisoners with type 1 diabetes and type 2 diabetes had 
several instances of inequitable diabetes health outcomes from April 2014-April 2020 in 
North Carolina. Examples of inequitable health outcomes included statistically 
significant and clinically significant differences in every health outcome measured when 
comparing active prisoners and recently released prisoners with type 1 diabetes to the 
non-prisoner status group. For type 2 diabetes, fewer differences were found, with only 
recently released prisoners differing statistically significantly from non-prisoners 
regarding the prevalence of ketoacidosis and hypoglycemia. The results of this study 
generally agreed with what is already known about the health of prisoners with chronic 
diseases and the health of recently released prisoners transitioning from incarceration. 
It was anticipated that this study focusing on diabetes would support established 
research suggesting that prisoners and recently released prisoners suffer from worse 
health outcomes when compared to non-prisoners and many of the findings were 
consistent with this expectation.3,4 
 
The study’s survey findings relating to the barriers that prisoners experience with their 
management of diabetes as perceived by medical providers also supported the main 
findings and current knowledge in literature. Most survey respondents identified aspects 
of prison that hamper ideal maintenance of one’s diabetes, especially for those with 
type 1 diabetes which requires insulin. The physician respondents believed that the 
timing of meals and snacks, restrictions relating to the administration of insulin, and 
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subpar care within prisons were the largest hurdles to proper management of diabetes 
for prisoner patients. Interventional policies targeting discrepancies in clinical outcomes 
should address these identified barriers while also considering the feasibility of a 
potential policy given the security requirements of a prison.   
 
There were numerous limitations within this study due to the difficult nature of studying 
prisoner populations. The study utilized aggregate data which can be limited in the 
generalizability of translating relationships seen at the macro level to the micro level.10 
The aggregate data was also limited by the lack of homogeneity from group to group 
with regards to group distributions of patient counts, age, gender, ethnicity, race, and 
geography. A strength of this study was its overall sample size (n=206,703) and ability 
to identify recently released prisoners through insurance payors, however limitations in 
the study did include some low resulting aggregate counts of less than 10 leading to 
censored data for case counts which limited the ability to analyze the data and created 
situations where no conclusions could be drawn. Additionally, the views of the UNC 
medical providers were a useful proxy for direct experiences of prisoner patients 
themselves due to the difficulty of involving prisoners within a research study since they 
are a vulnerable group as determined by the Institutional Review Board, but were still a 
limitation as they are not as familiar with the day-to-day aspects of prison that prisoners 
experience and cannot substitute directly for directly surveying prisoners.11 Lastly, the 
study only used samples from North Carolina which also limits the generalizability of the 
data.  
 
Within type 1 diabetes prisoner status groups we see that active prisoners and recently 
released prisoners differed significantly to non-prisoners for the prevalence of 
ketoacidosis, hypoglycemia, and mean HbA1c. For type 2 diabetes we see that active 
prisoners and non-prisoners did not differ significantly, however, the recently released 
prisoner group did differ significantly to the non-prisoner group when looking at 
prevalence of ketoacidosis and hypoglycemia. These findings seem to suggest that the 
current prison environment does not significantly worsen health outcomes for those with 
type 2 diabetes compared to their non-incarcerated peers, but the complication of 
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administering insulin within prison significantly exacerbates type 1 diabetes health 
outcomes. When transitioning out of prison, recently released prisoners are faced with 
different hurdles that stem from a lack of support with regards to health insurance, 
stable housing, and income. The statistically significant differences found within the 
recently released prisoner status group for both type 1 and 2 diabetes may suggest that 
patients with diabetes leaving prison do not have enough support and resources to 
effectively manage their condition. 
 
 
Public Health Implications 
These results are relevant to public health by suggesting additional targeted efforts 
need to be made to improve health equity amongst prisoners and recently released 
prisoners. The results suggest that prisoner diabetes patients and recently released 
prisoner diabetes patients do not participate in healthy diabetes related behaviors at the 
level that non-prisoners do. Since the United States is the current leader of 
incarceration rates amongst industrialized nations, this implies that a large demographic 
with diabetes is suffering from worse health outcomes leading to unnecessarily heavy 
strain on our healthcare system, in addition to the moral dilemma of the current lack of 
intervention to aid prisoner patients and recently released prisoner patients for the sake 
of their own health.12 
 
This study highlights the worse health outcomes that prisoners and recently released 
prisoners with diabetes are experiencing when compared to those who have not been 
incarcerated and offers some avenues for future research to potentially lead to public 
health interventions. Future studies will need to be conducted to further support our 
findings and to address the limitations experienced in this study by including direct 
testimonials from prisoners themselves, patient level data, and samples composed of 
national prison populations to help improve the generalizability of the results. Future 
study efforts should also be made to review existing policies and the compliance of 





Potential recommendations can be made to help attempt to address the discrepancies 
in health outcomes found such as improving the timing of meals paired with improved 
access to insulin administration. Specifically relating to Covid-19, a North Carolina 
Regional Medical Director conveyed difficulties logistically aligning insulin administration 
with eating schedules since some prisons have now adopted a wider range of eating 
times to minimize the group size of prisoners eating at a time.13  
 
The findings on the health of recently released prisoners could also influence the 
allocation of federal or state funding to provide medication supplies to newly released 
prisoners and to improve the health insurance transition for prisoners. Once out of 
prison, many prisoners face situations where they no longer have health insurance, 
falling into a gap where they do not qualify for Medicaid, but also cannot afford market 
rate health insurance.14 Even the people with diabetes transitioning out of prison who do 
qualify for Medicaid may face coverage gaps due to timeliness of Medicaid approval if 
they did not enroll in Medicaid prior to their release. From 2011-2015 North Carolina 
processed fewer applications in a timely manner year over year with only 61% of 
applications being processed within 45 days from 2014-2015.15 Community health 
centers are a federally funded option available to newly released prisoners for care, but 
their accessibility could be greatly improved with federal programs providing free or 
subsidized transportation to these centers for patients recently released from prison. 
Within these community health centers, financial barriers still exist that can make it 
difficult for a low-income patient to schedule a timely appointment with a clinic due to 
copayments of $20-25 for an office visit and additional payments of $4-10 for 
medications.16 Lastly, connecting patients with a medical provider in their community 
upon release could potentially help to reduce the discrepancy found in health outcomes. 
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Tables for AJPH Submission: 
Table 1. Occurence of DKA and 
Hypoglycemia from April, 
2014-April, 2020 by Prisoner 







Chi squared test 
of independence   
    X2 df p-value 
Type 1 Diabetes 77 16 7748    
DKA 0.2727 <10 0.1618 8.06/25.46 2 0.0177/<0.00001 
No DKA 0.7273 NA 0.8382    
Hypoglycemia 0.4416 0.6250 0.2435 28.49 2 <0.00001 
No Hypoglycemia 0.5584 0.3750 0.7565    
       
Type 2 Diabetes 1250 255 197357    
DKA 0.0152 0.0471 0.0153 16.97 2 0.0002 
No DKA 0.9848 0.9529 0.9847    
Hypoglycemia 0.0608 0.0824 0.0486 10.21 2 0.0060 
No Hypoglycemia 0.9392 0.9176 0.9514    
† Sensitivity analysis was run for DKA of recently released prisoners generating conservative/liberal X2 
and p-values 
Table 2. Post-hoc pairwise comparisons by 
prison status group (difference of 









Prisoner vs. Never 
Prisoner 
Type 1 Diabetes    
DKA NA 2.62* NA 
Hypoglycemia 1.33 4.01* 3.54* 
HbA1c 0.44 1.37* 1.81* 
Type 2 Diabetes    
DKA 3.62* 0.02 4.12* 
Hypoglycemia 1.28 1.99 2.50* 
HbA1c 0.49 0.20 0.69 
*denotes significance at alpha (0.05/3) 
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Table 3. Mean HbA1c from April, 2014-April, 






Prisoner  F 
p-
value 
 (Mean)     
Type 1 Diabetes 9.71 10.15 8.34 21.5969 0.0000 
Type 2 Diabetes 7.5 7.99 7.3 4.330 0.0132 
 
Table 4. Medical Provider Perceptions to Barriers of Care for Prisoners 
Survey Results (n=13)  
Obstacles 
Mean Perceived Impact 
(0-100) 
Overall Prison Impact on Health 77 
Timing of meals and snacks 76 
Lack of freedom to administer insulin 73 
Quality of care within the prison facilities 71 
Diabetes knowledge of prisoners themselves 70 
Overall quality of diet 66 
Lack of continuity of care from leaving their communities 66 
Insufficient diabetes knowledge of prison officials 63 
Insufficient prison funding 62 
Lack of continuity of care within the prison system through prison transfers 49 
Social stigma of having a chronic disease within prison 47 





Prisoners with diabetes undoubtedly face conditions that the average non-incarcerated 
individual with diabetes does not. Medical providers responding to the survey asking for 
their perceptions of the barriers to care that prisoners experience believed that a 
multitude of factors greatly contribute as barriers to proper diabetes management for 
prisoners. Of note, the medical providers viewed the restricted freedom to time one’s 
own meals and snacks, administer their own insulin, and the quality of care within the 
prisons as the top drivers for inequitable health outcomes for prisoners with diabetes. 
 
North Carolina Department of Public Safety regional medical director, Dr. Neva 
Bartholomew, confirmed that many of these perceived barriers were valid. Despite 
many prisons having good intentions and trying hard to take care of their prisoners, 
there are some characteristics of the prison system today that make it more difficult to 
achieve equitable care. Prisoners have scheduled mealtimes that are dictated to them 
and it becomes a logistical challenge for prison nurses to properly administer insulin in 
concordance with the scheduled meal for every prisoner who has diabetes and requires 
insulin. This logistical challenge has only been exacerbated during COVID-19 in which 
prisoners are split into smaller groups for meals making it harder for the nurses to keep 
track of when to administer insulin. The medical director also confirmed that quality of 
care within prisons are inherently not equitable to care received by non-incarcerated 
patients with diabetes due to limitations on medications. Prisons generally have access 
to medications that have a proven track record and are the standard for the condition, 
but they have limited access to newer medications that could benefit someone who was 
not responding well to older medication. Additionally, it is important to consider the 
mental health and motivation of prisoners themselves to adhere to proper management. 
As related by the medical director, prisoners are informed on dietary and exercise 
management for their condition by providers but will still frequently purchase unhealthy 
snacks and drinks from the commissary. This deviance could be due to several reasons 
such as apathy to adhere to proper management while imprisoned or an ill-placed effort 




Dr. Ashkin also shared his thoughts and experiences with recently released prisoners 
and conveyed a situation that is not conducive for adequate diabetes management. 
Prisoners are oftentimes released with no health insurance or transition of care plan. 
Due to political decisions regarding Medicaid expansion, there exists a demographic of 
prisoners who simultaneously cannot afford health insurance and do not qualify for 
Medicaid. Low-income community health centers do exist, but many of them are not 
able to see patients on short notice and have low-cost copays that still present financial 
barriers for someone recently released from prison. Many recently released prisoners 
also face the burdens of housing, food, and income insecurities in addition to parole 
requirements. These factors all contribute to making the management of one’s diabetes 
harder and the de-prioritization of their diabetes when faced with seemingly more 
pressing concerns, such as finding a job and housing or abiding by parole requirements 
to avoid returning to prison. 
 
Given this context, the results of our study finding statistically significant differences in 
the health outcomes of prisoners and recently released prisoners with diabetes when 
compared to non-incarcerated diabetes patients follows the theoretical framework in 
place. In general, we found that prisoners and recently released prisoners with type 1 
diabetes differed significantly from non-incarcerated patients with diabetes in regard to 
prevalence of ketoacidosis, hypoglycemia, and mean HbA1c. Among those with type 2 
diabetes, we found that only the recently released prisoners differed significantly for the 
prevalence of ketoacidosis and hypoglycemia. No significant differences between active 
prisoners and non-incarcerated diabetes patients with type 2 diabetes were found.  
 
These findings seem to suggest that policy changes and resources should be directed 
towards making the administration of insulin a more seamless process within prison and 
to transform the transition out of prison by increasing the amount of support that 
released prisoners have. Policy reform with these goals in mind will be helpful to 
improve equitable health outcomes of type 1 diabetes prisoners and recently released 
prisoners of both type 1 and type 2 diabetes. 
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Further studies will need to be conducted to investigate our findings and address the 
limitations seen within our study. Limitations include the lack of patient level data, lack 
of direct responses and testimonials from prisoners and recently released prisoners, 
wide ranging sample sizes, insufficient demographic data, and a sample that is only 
reflective of North Carolina. Future studies will also need to take place to investigate the 
impact of any policies made in attempts to address any discrepancies seen in the health 
outcomes of prisoners and recently released prisoners with diabetes and compliance of 




Medical Provider Questionnaire: 
Q1 University of North Carolina at Chapel Hill   
Research Information Sheet   
IRB Study #: 20-0594   
Principal Investigator: Julien DuBois      
The purpose of this research study is to see what barriers to care prisoners with diabetes 
experience as perceived by medical providers.  You are being asked to take part in a research 
study because you:   
 
 -You are a practicing medical provider 
-You regularly treat diabetes patients 
-You have treated incarcerated diabetes patients before      
  
Being in a research study is completely voluntary. You can choose not to be in this research 
study. You can also say yes now and change your mind later. Participation will not affect your 
relationship with UNC.      
 
If you agree to take part in this research, you will be asked to take a one-time survey on your 
perceptions of barriers to care for prisoners with diabetes. Your participation in this study will 
take about 5-10 minutes.       
 
You can choose not to answer any question you do not wish to answer. You can also choose to 
stop taking the survey at any time.       
 
The possible risks to you in taking part in this research are: 
-Having someone else find out that you were in a research study  
-Potential loss of confidential information   
 
To protect your identity as a research subject, the research data will not be stored with your 
name, the researchers will not share your information with anyone. In any publication about this 




If you have any questions about this research, please contact the Investigator named at the top 
of this form by calling 919-448-6855 or emailing juliend@live.unc.edu. If you have questions or 
concerns about your rights as a research subject, you may contact the UNC Institutional Review 
Board at 919-966-3113 or by email to IRB_subjects@unc.edu. 
o I consent to participate  (1)  
o I do not consent to participate  (2)  
 










Q4 What type of medical provider are you? 
o Physician  (1)  
o Other  (2)  




Q5 Do you believe that the majority of prisons in North Carolina follow the clinical guidance for 
the management of diabetes as determined by the Federal Bureau of Prisons?  
o Yes  (1)  
o No  (2)  






Q6 How large, if any, of an impact does being in prison have on the health of prisoners with 
diabetes?      (0=No Impact     100=Large Impact) 
 0 10 20 30 40 50 60 70 80 90 100 
 






Q7 How much do the following create a barrier to proper diabetes management in prisons? 
Questions answered on a scale of 0-100 (0=No Impact 100=Large Impact) 
 
 0 10 20 30 40 50 60 70 80 90 100 
 
Insufficient diabetes knowledge of prison 
officials () 
 
Diabetes knowledge of prisoners themselves 
() 
 
Lack of freedom to administer insulin () 
 
Overall quality of diet () 
 
Timing of meals and snacks () 
 
Insufficient physical activity () 
 
Lack of continuity of care from leaving their 
communities () 
 
Lack of continuity of care within the prison 




Quality of care within the prison facilities () 
 
Social stigma of having a chronic disease 
within prison () 
 
























Q10 How do you believe the following prison characteristics impact the health outcomes of 
diabetes patients in prison?  (1=Significantly negatively impacts   3=No impact   5=Significantly 
positively impacts) 




Prisons being public rather than private () 
 
Being held in a lower security level rather 
than a higher level () 
 
Prison population size being smaller rather 






Q11 What do you see as the most important problem facing incarcerated diabetes patients as it 

























Effect Modification Tables: 
 
Table 5. Chi Squared statistics for 
hypoglycemia for each demographic 
stratified prevalence difference among 
people with Type 1 Diabetes 





Chi squared test 
of independence 
  




50 or Above 
     
Hypo 15 893 13.6 1 0.0002 
No Hypo 11 2565 














Female=0 980/3097 0 (ref.) NA NA NA NA NA NA
Male=1 906/2764 0.006493662 NA NA NA NA NA NA
50 or above=0 893/2565 0 (ref.) NA NA 15/11 0.318681 NA
0.318 (0.264, 
0.372)
<50=1 994/3296 -0.02654 NA NA 19/32 0.114307 NA
0.140 (0.124, 
0.157)
White=0 1329/4028 0 (ref.) NA NA 16/20 0.196358 NA
0.196 (0.168, 
0.224)




Female=0 5177/99780 0 (ref.) <10/(45- <10) NA 12/188 0.010675 NA
0.0106, (0.0103, 
0.0109)
Male=1 4416/87972 -0.001526546 */(212-*) NA 64/986 0.011627 NA
0.0131, (0.0129, 
0.0133)
50 or above=0 8570/158372 0 (ref.) NA NA 64/921 0.013639 NA
0.0136, (0.0134, 
0.0138)
<50=1 1023/27119 -0.01498 NA NA 12/253 -0.00605 NA
0.0089, (0.0087, 
0.0091)
White=0 5354/111565 0 (ref.) NA NA 30/462 0.015183 NA
-0.0208, (-
0.0204, -0.0212)
Non-white=1 4239/76199 0.006907 NA NA 46/712 0.014894 NA
0.0079, (0.0078, 
0.0081)
Table 4. Effect modification of hypoglycemic events by demographics on prison status group 


















     
Hypo 19 994 5.58 1 0.018 
No Hypo 32 3296 
   
White 
     
Hypo 16 1329 7.36 1 0.0066 
No Hypo 20 4028 
   
Non-white 
     
Hypo 18 558 9.43 1 0.0021 
No Hypo 23 1833 
   
 
Table 6. Chi Squared statistics for 
hypoglycemia for each demographic 
stratified prevalence difference among 
people with Type 2 Diabetes 





Chi squared test 
of independence 
  





     
Hypo 12 5177 0.84 1 0.3589 
No Hypo 176 99780 
   
Male 
     
Hypo 64 4416 3.93 1 0.0472 
No Hypo 986 87972 
   
50 or Above 
     
Hypo 64 8570 3.73 1 0.0532 
No Hypo 921 158372 
   
<50 
     
Hypo 12 1023 0.59 1 0.4398 
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No Hypo 253 27119 
   
White 
     
Hypo 30 5354 2.58 1 0.1081 
No Hypo 462 111565 
   
Non-white 
     
Hypo 46 4239 0.95 1 0.3276 
No Hypo 712 76199 
   
 
Survey Policy Suggestions Table: 
Table 7. Suggested policy changes from survey results 
 
Improved utilization of Diabetes protocols and nurse coordinators 
Changes in diet/Expanding dietary options and timing 
Improved transitional care plan when exiting prison 
Improving the array of medications available for people with type 2 diabetes 
Improved access to endocrinologists and nutritionists through telemedicine 
Greater freedom/ability to administer insulin 
 
Diabetic Ketoacidosis ICD Codes: 
DKA ICD-9 Codes  Description 
250.1  Diabetes with Ketoacidosis  
249.1  Secondary Diabetes mellitus with 
ketoacidosis  
276.2  Acidosis  
 
DKA ICD-10 Codes  Description 
E09.10  Drug/Chem diabetes mellitus w ketoacidosis w/o coma  
E09.11  Drug/Chem diabetes mellitus w ketoacidosis w coma  
E13.10  Other specified diabetes mellitus with ketoacidosis without 
coma  




E10.10  Type 1 diabetes mellitus with ketoacidosis without coma  
E10.11  Type 1 diabetes mellitus with ketoacidosis with coma  
E11.10  Type 2 diabetes mellitus with ketoacidosis without coma  
E11.11  Type 2 diabetes mellitus with ketoacidosis with coma  
E08.10  Diabetes due to underlying condition w ketoacidosis w/o 
coma  
E08.11  Diabetes due to underlying condition with ketoacidosis with 
coma  
 




251.2  Hypoglycemia, 
unspecified  
251.1  Other specified 
hypoglycemia  
251  Hypoglycemic coma  
 
Hypoglycemia 
ICD-10 Codes  
Description 
E16.2  Hypoglycemia, unspecified  
E16.0  Drug-induced hypoglycemia without coma  
E16.1  Other Hypoglycemia  
E09.641  Drug/Chem diabetes mellitus with hypoglycemia with coma  
E13.641  Other Diabetes mellitus with hypoglycemia with coma  
E09.649  Drug/chem diabetes mellitus with hypoglycemia w/o coma  
E13.649  Other diabetes mellitus with hypoglycemia without coma  
E10.641  Type 1 diabetes mellitus with hypoglycemia with coma  
E11.641  Type 2 diabetes mellitus with hypoglycemia with coma  
E10.649  Type 1 diabetes mellitus with hypoglycemia without coma  
E11.649  Type 2 diabetes mellitus with hypoglycemia without coma  
E10.64  Type 1 diabetes mellitus with hypoglycemia  
E11.64  Type 2 diabetes mellitus with hypoglycemia  
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E13.64  Other specified diabetes mellitus with hypoglycemia  
E08.641  Diabetes due to underlying condition w hypoglycemia w coma  
E08.649  Diabetes due to underlying condition w hypoglycemia w/o coma  
E08.64  Diabetes mellitus due to underlying condition with hypoglycemia   
E09.64  Drug or chemical induced diabetes mellitus with hypoglycemia  
T38.3  Poisoning by, adverse effect of and underdosing of insulin and oral 
hypoglycemic [antidiabetic] drugs  
 




250.01 Type I (juvenile type) diabetes mellitus without mention of 
complication, not stated as uncontrolled 
250.03 Type I (juvenile type) diabetes mellitus without mention of 
complication, uncontrolled 
250.11 Type I (juvenile type) diabetes mellitus with ketoacidosis, not stated 
as uncontrolled(250.11) 
250.13 Type I (juvenile type) diabetes mellitus with ketoacidosis, 
uncontrolled 
250.21 Type I (juvenile type) diabetes mellitus with hyperosmolarity, not 
stated as uncontrolled 
250.23 Type I (juvenile type) diabetes mellitus with hyperosmolarity, 
uncontrolled 
250.31 Type I (juvenile type) diabetes mellitus with other coma, not stated as 
uncontrolled 
250.33 Type I (juvenile type) diabetes mellitus with other coma, uncontrolled 
250.41 Type I (juvenile type) diabetes mellitus with renal manifestations, not 
stated as uncontrolled(250.41) 
250.43 Type I (juvenile type) diabetes mellitus with renal manifestations, 
uncontrolled(250.43) 
250.51 Type I (juvenile type) diabetes mellitus with ophthalmic 
manifestations, not stated as uncontrolled(250.51) 
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250.53 Type I (juvenile type) diabetes mellitus with ophthalmic 
manifestations, uncontrolled(250.53) 
250.61 Type I (juvenile type) diabetes mellitus with neurological 
manifestations, not stated as uncontrolled(250.61) 
250.63 Type I (juvenile type) diabetes mellitus with neurological 
manifestations, uncontrolled(250.63) 
250.71 Type I (juvenile type) diabetes mellitus with peripheral circulatory 
disorders, not stated as uncontrolled(250.71) 
250.73 Type I (juvenile type) diabetes mellitus with peripheral circulatory 
disorders, uncontrolled(250.73) 
250.81 Type I (juvenile type) diabetes mellitus with other specified 
manifestations, not stated as uncontrolled 
250.83 Type I (juvenile type) diabetes mellitus with other specified 
manifestations, uncontrolled 
250.91 Type I (juvenile type) diabetes mellitus with unspecified complication, 
not stated as uncontrolled 






E10 Type 1 diabetes mellitus 
E10.1 Type 1 diabetes mellitus with ketoacidosis 
E10.10 Type 1 diabetes mellitus with ketoacidosis without coma 
E10.11 Type 1 diabetes mellitus with ketoacidosis with coma 
E10.2 Type 1 diabetes mellitus with kidney complications 
E10.21 Type 1 diabetes mellitus with diabetic nephropathy 
E10.22 Type 1 diabetes mellitus with diabetic chronic kidney disease 
E10.29 Type 1 diabetes mellitus with other diabetic kidney complication 
E10.3 Type 1 diabetes mellitus with ophthalmic complications 
E10.31 Type 1 diabetes mellitus with unspecified diabetic retinopathy 




E10.319 Type 1 diabetes mellitus with unspecified diabetic retinopathy without 
macular edema 
E10.32 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy 
E10.321 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with 
macular edema 
E10.3211 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with 
macular edema, right eye 
E10.3212 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with 
macular edema, left eye 
E10.3213 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with 
macular edema, bilateral 
E10.3219 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with 
macular edema, unspecified eye 
E10.329 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy 
without macular edema 
E10.3291 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy 
without macular edema, right eye 
E10.3292 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy 
without macular edema, left eye 
E10.3293 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy 
without macular edema, bilateral 
E10.3299 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy 
without macular edema, unspecified eye 
E10.33 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
E10.331 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
with macular edema 
E10.3311 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
with macular edema, right eye 
E10.3312 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
with macular edema, left eye 
E10.3313 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
with macular edema, bilateral 
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E10.3319 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
with macular edema, unspecified eye 
E10.339 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
without macular edema 
E10.3391 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
without macular edema, right eye 
E10.3392 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
without macular edema, left eye 
E10.3393 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
without macular edema, bilateral 
E10.3399 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
without macular edema, unspecified eye 
E10.34 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy 
E10.341 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy 
with macular edema 
E10.3411 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy 
with macular edema, right eye 
E10.3412 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy 
with macular edema, left eye 
E10.3413 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy 
with macular edema, bilateral 
E10.3419 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy 
with macular edema, unspecified eye 
E10.349 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy 
without macular edema 
E10.3491 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy 
without macular edema, right eye 
E10.3492 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy 
without macular edema, left eye 
E10.3493 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy 
without macular edema, bilateral 
E10.3499 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy 
without macular edema, unspecified eye 
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E10.35 Type 1 diabetes mellitus with proliferative diabetic retinopathy 
E10.351 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular 
edema 
E10.3511 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular 
edema, right eye 
E10.3512 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular 
edema, left eye 
E10.3513 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular 
edema, bilateral 
E10.3519 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular 
edema, unspecified eye 
E10.352 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment involving the macula 
E10.3521 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment involving the macula, right eye 
E10.3522 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment involving the macula, left eye 
E10.3523 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment involving the macula, bilateral 
E10.3529 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment involving the macula, unspecified eye 
E10.353 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment not involving the macula 
E10.3531 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment not involving the macula, right eye 
E10.3532 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment not involving the macula, left eye 
E10.3533 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment not involving the macula, bilateral 
E10.3539 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment not involving the macula, unspecified eye 
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E10.354 Type 1 diabetes mellitus with proliferative diabetic retinopathy with 
combined traction retinal detachment and rhegmatogenous retinal 
detachment 
E10.3541 Type 1 diabetes mellitus with proliferative diabetic retinopathy with 
combined traction retinal detachment and rhegmatogenous retinal 
detachment, right eye 
E10.3542 Type 1 diabetes mellitus with proliferative diabetic retinopathy with 
combined traction retinal detachment and rhegmatogenous retinal 
detachment, left eye 
E10.3543 Type 1 diabetes mellitus with proliferative diabetic retinopathy with 
combined traction retinal detachment and rhegmatogenous retinal 
detachment, bilateral 
E10.3549 Type 1 diabetes mellitus with proliferative diabetic retinopathy with 
combined traction retinal detachment and rhegmatogenous retinal 
detachment, unspecified eye 
E10.355 Type 1 diabetes mellitus with stable proliferative diabetic retinopathy 
E10.3551 Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right 
eye 
E10.3552 Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left 
eye 
E10.3553 Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, 
bilateral 
E10.3559 Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, 
unspecified eye 
E10.359 Type 1 diabetes mellitus with proliferative diabetic retinopathy without 
macular edema 
E10.3591 Type 1 diabetes mellitus with proliferative diabetic retinopathy without 
macular edema, right eye 
E10.3592 Type 1 diabetes mellitus with proliferative diabetic retinopathy without 
macular edema, left eye 
E10.3593 Type 1 diabetes mellitus with proliferative diabetic retinopathy without 
macular edema, bilateral 
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E10.3599 Type 1 diabetes mellitus with proliferative diabetic retinopathy without 
macular edema, unspecified eye 
E10.36 Type 1 diabetes mellitus with diabetic cataract 
E10.37 Type 1 diabetes mellitus with diabetic macular edema, resolved following 
treatment 
E10.37X1 Type 1 diabetes mellitus with diabetic macular edema, resolved following 
treatment, right eye 
E10.37X2 Type 1 diabetes mellitus with diabetic macular edema, resolved following 
treatment, left eye 
E10.37X3 Type 1 diabetes mellitus with diabetic macular edema, resolved following 
treatment, bilateral 
E10.37X9 Type 1 diabetes mellitus with diabetic macular edema, resolved following 
treatment, unspecified eye 
E10.39 Type 1 diabetes mellitus with other diabetic ophthalmic complication 
E10.4 Type 1 diabetes mellitus with neurological complications 
E10.40 Type 1 diabetes mellitus with diabetic neuropathy, unspecified 
E10.41 Type 1 diabetes mellitus with diabetic mononeuropathy 
E10.42 Type 1 diabetes mellitus with diabetic polyneuropathy 
E10.43 Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy 
E10.44 Type 1 diabetes mellitus with diabetic amyotrophy 
E10.49 Type 1 diabetes mellitus with other diabetic neurological complication 
E10.5 Type 1 diabetes mellitus with circulatory complications 
E10.51 Type 1 diabetes mellitus with diabetic peripheral angiopathy without 
gangrene 
E10.52 Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene 
E10.59 Type 1 diabetes mellitus with other circulatory complications 
E10.6 Type 1 diabetes mellitus with other specified complications 
E10.61 Type 1 diabetes mellitus with diabetic arthropathy 
E10.610 Type 1 diabetes mellitus with diabetic neuropathic arthropathy 
E10.618 Type 1 diabetes mellitus with other diabetic arthropathy 
E10.62 Type 1 diabetes mellitus with skin complications 
E10.620 Type 1 diabetes mellitus with diabetic dermatitis 
E10.621 Type 1 diabetes mellitus with foot ulcer 
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E10.622 Type 1 diabetes mellitus with other skin ulcer 
E10.628 Type 1 diabetes mellitus with other skin complications 
E10.63 Type 1 diabetes mellitus with oral complications 
E10.630 Type 1 diabetes mellitus with periodontal disease 
E10.638 Type 1 diabetes mellitus with other oral complications 
E10.64 Type 1 diabetes mellitus with hypoglycemia 
E10.640 Type 1 diabetes mellitus with hypoglycemia without coma 
E10.641 Type 1 diabetes mellitus with hypoglycemia with coma 
E10.649 Type 1 diabetes mellitus with hypoglycemia without coma 
E10.65 Type 1 diabetes mellitus with hyperglycemia 
E10.69 Type 1 diabetes mellitus with other specified complication 
E10.8 Type 1 diabetes mellitus with unspecified complications 
E10.9 Type 1 diabetes mellitus without complications 
O24.02 Pre-existing type 1 diabetes mellitus, in childbirth 
O24.03 Pre-existing type 1 diabetes mellitus, in the puerperium 
 




250 Type II or unspecified type diabetes mellitus without mention of 
complication, not stated as uncontrolled 
250.02 Type II or unspecified type diabetes mellitus without mention of 
complication, uncontrolled 
250.1 Type II or unspecified type diabetes mellitus with ketoacidosis, not 
stated as uncontrolled 
250.12 Type II or unspecified type diabetes mellitus with ketoacidosis, 
uncontrolled(250.12) (CMS-HCC) 
250.2 Type II or unspecified type diabetes mellitus with hyperosmolarity, not 
stated as uncontrolled 
250.22 Type II or unspecified type diabetes mellitus with hyperosmolarity, 
uncontrolled 
250.3 Type II or unspecified type diabetes mellitus with other coma, not 
stated as uncontrolled 
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250.32 Type II or unspecified type diabetes mellitus with other coma, 
uncontrolled 
250.4 Type II or unspecified type diabetes mellitus with renal manifestations, 
not stated as uncontrolled(250.40) 
250.42 Type II or unspecified type diabetes mellitus with renal manifestations, 
uncontrolled(250.42) 
250.5 Type II or unspecified type diabetes mellitus with ophthalmic 
manifestations, not stated as uncontrolled(250.50) 
250.52 Type II or unspecified type diabetes mellitus with ophthalmic 
manifestations, uncontrolled(250.52) 
250.6 Type II or unspecified type diabetes mellitus with neurological 
manifestations, not stated as uncontrolled(250.60) 
250.62 Type II or unspecified type diabetes mellitus with neurological 
manifestations, uncontrolled(250.62) 
250.7 Type II or unspecified type diabetes mellitus with peripheral 
circulatory disorders, not stated as uncontrolled(250.70) 
250.72 Type II or unspecified type diabetes mellitus with peripheral 
circulatory disorders, uncontrolled(250.72) 
250.8 Type II or unspecified type diabetes mellitus with other specified 
manifestations, not stated as uncontrolled 
250.82 Type II or unspecified type diabetes mellitus with other specified 
manifestations, uncontrolled 
250.9 Type II or unspecified type diabetes mellitus with unspecified 
complication, not stated as uncontrolled 






E11 Type 2 diabetes mellitus 
E11.0 Type 2 diabetes mellitus with hyperosmolarity 
E11.00 Type 2 diabetes mellitus with hyperosmolarity without nonketotic 
hyperglycemic-hyperosmolar coma (NKHHC) 
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E11.01 Type 2 diabetes mellitus with hyperosmolarity with coma 
E11.1 Type 2 diabetes mellitus with ketoacidosis 
E11.10 Type 2 diabetes mellitus with ketoacidosis without coma 
E11.11 Type 2 diabetes mellitus with ketoacidosis with coma 
E11.2 Type 2 diabetes mellitus with kidney complications 
E11.21 Type 2 diabetes mellitus with diabetic nephropathy 
E11.22 Type 2 diabetes mellitus with diabetic chronic kidney disease 
E11.29 Type 2 diabetes mellitus with other diabetic kidney complication 
E11.3 Type 2 diabetes mellitus with ophthalmic complications 
E11.31 Type 2 diabetes mellitus with unspecified diabetic retinopathy 
E11.311 Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular 
edema 
E11.319 Type 2 diabetes mellitus with unspecified diabetic retinopathy without 
macular edema 
E11.32 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy 
E11.321 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with 
macular edema 
E11.3211 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with 
macular edema, right eye 
E11.3212 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with 
macular edema, left eye 
E11.3213 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with 
macular edema, bilateral 
E11.3219 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with 
macular edema, unspecified eye 
E11.329 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy 
without macular edema 
E11.3291 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy 
without macular edema, right eye 
E11.3292 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy 
without macular edema, left eye 
E11.3293 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy 
without macular edema, bilateral 
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E11.3299 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy 
without macular edema, unspecified eye 
E11.33 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
E11.331 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
with macular edema 
E11.3311 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
with macular edema, right eye 
E11.3312 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
with macular edema, left eye 
E11.3313 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
with macular edema, bilateral 
E11.3319 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
with macular edema, unspecified eye 
E11.339 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
without macular edema 
E11.3391 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
without macular edema, right eye 
E11.3392 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
without macular edema, left eye 
E11.3393 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
without macular edema, bilateral 
E11.3399 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy 
without macular edema, unspecified eye 
E11.34 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy 
E11.341 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy 
with macular edema 
E11.3411 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy 
with macular edema, right eye 
E11.3412 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy 
with macular edema, left eye 
E11.3413 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy 
with macular edema, bilateral 
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E11.3419 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy 
with macular edema, unspecified eye 
E11.349 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy 
without macular edema 
E11.3491 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy 
without macular edema, right eye 
E11.3492 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy 
without macular edema, left eye 
E11.3493 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy 
without macular edema, bilateral 
E11.3499 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy 
without macular edema, unspecified eye 
E11.35 Type 2 diabetes mellitus with proliferative diabetic retinopathy 
E11.351 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular 
edema 
E11.3511 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular 
edema, right eye 
E11.3512 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular 
edema, left eye 
E11.3513 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular 
edema, bilateral 
E11.3519 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular 
edema, unspecified eye 
E11.352 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment involving the macula 
E11.3521 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment involving the macula, right eye 
E11.3522 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment involving the macula, left eye 
E11.3523 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment involving the macula, bilateral 
E11.3529 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment involving the macula, unspecified eye 
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E11.353 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment not involving the macula 
E11.3531 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment not involving the macula, right eye 
E11.3532 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment not involving the macula, left eye 
E11.3533 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment not involving the macula, bilateral 
E11.3539 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction 
retinal detachment not involving the macula, unspecified eye 
E11.354 Type 2 diabetes mellitus with proliferative diabetic retinopathy with 
combined traction retinal detachment and rhegmatogenous retinal 
detachment 
E11.3541 Type 2 diabetes mellitus with proliferative diabetic retinopathy with 
combined traction retinal detachment and rhegmatogenous retinal 
detachment, right eye 
E11.3542 Type 2 diabetes mellitus with proliferative diabetic retinopathy with 
combined traction retinal detachment and rhegmatogenous retinal 
detachment, left eye 
E11.3543 Type 2 diabetes mellitus with proliferative diabetic retinopathy with 
combined traction retinal detachment and rhegmatogenous retinal 
detachment, bilateral 
E11.3549 Type 2 diabetes mellitus with proliferative diabetic retinopathy with 
combined traction retinal detachment and rhegmatogenous retinal 
detachment, unspecified eye 
E11.355 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy 
E11.3551 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right 
eye 
E11.3552 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left 
eye 




E11.3559 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, 
unspecified eye 
E11.359 Type 2 diabetes mellitus with proliferative diabetic retinopathy without 
macular edema 
E11.3591 Type 2 diabetes mellitus with proliferative diabetic retinopathy without 
macular edema, right eye 
E11.3592 Type 2 diabetes mellitus with proliferative diabetic retinopathy without 
macular edema, left eye 
E11.3593 Type 2 diabetes mellitus with proliferative diabetic retinopathy without 
macular edema, bilateral 
E11.3599 Type 2 diabetes mellitus with proliferative diabetic retinopathy without 
macular edema, unspecified eye 
E11.36 Type 2 diabetes mellitus with diabetic cataract 
E11.37 Type 2 diabetes mellitus with diabetic macular edema, resolved following 
treatment 
E11.37X1 Type 2 diabetes mellitus with diabetic macular edema, resolved following 
treatment, right eye 
E11.37X2 Type 2 diabetes mellitus with diabetic macular edema, resolved following 
treatment, left eye 
E11.37X3 Type 2 diabetes mellitus with diabetic macular edema, resolved following 
treatment, bilateral 
E11.37X9 Type 2 diabetes mellitus with diabetic macular edema, resolved following 
treatment, unspecified eye 
E11.39 Type 2 diabetes mellitus with other diabetic ophthalmic complication 
E11.4 Type 2 diabetes mellitus with neurological complications 
E11.40 Type 2 diabetes mellitus with diabetic neuropathy, unspecified 
E11.41 Type 2 diabetes mellitus with diabetic mononeuropathy 
E11.42 Type 2 diabetes mellitus with diabetic polyneuropathy 
E11.43 Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy 
E11.44 Type 2 diabetes mellitus with diabetic amyotrophy 
E11.49 Type 2 diabetes mellitus with other diabetic neurological complication 
E11.5 Type 2 diabetes mellitus with circulatory complications 
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E11.51 Type 2 diabetes mellitus with diabetic peripheral angiopathy without 
gangrene 
E11.52 Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene 
E11.59 Type 2 diabetes mellitus with other circulatory complications 
E11.6 Type 2 diabetes mellitus with other specified complications 
E11.61 Type 2 diabetes mellitus with diabetic arthropathy 
E11.610 Type 2 diabetes mellitus with diabetic neuropathic arthropathy 
E11.618 Type 2 diabetes mellitus with other diabetic arthropathy 
E11.62 Type 2 diabetes mellitus with skin complications 
E11.620 Type 2 diabetes mellitus with diabetic dermatitis 
E11.621 Type 2 diabetes mellitus with foot ulcer 
E11.622 Type 2 diabetes mellitus with other skin ulcer 
E11.628 Type 2 diabetes mellitus with other skin complications 
E11.63 Type 2 diabetes mellitus with oral complications 
E11.630 Type 2 diabetes mellitus with periodontal disease 
E11.638 Type 2 diabetes mellitus with other oral complications 
E11.64 Type 2 diabetes mellitus with hypoglycemia 
E11.640 Type 2 diabetes mellitus with hypoglycemia without coma 
E11.641 Type 2 diabetes mellitus with hypoglycemia with coma 
E11.649 Type 2 diabetes mellitus with hypoglycemia without coma 
E11.65 Type 2 diabetes mellitus with hyperglycemia 
E11.69 Type 2 diabetes mellitus with other specified complication 
E11.8 Type 2 diabetes mellitus with unspecified complications 
E11.9 Type 2 diabetes mellitus without complications 
O24.12 Pre-existing type 2 diabetes mellitus, in childbirth 
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